A free app that’s all carrot, no stick — offering users loyalty points for completing quizzes and surveys about healthy living — has gotten a $1.5 million boost from the Ontario government. The Toronto-based company behind it said “we are a nation so addicted to our phones and also incredibly addicted to...Read the Full Article
President Trump has named Norman “Ned” Sharpless, the director of the University of North Carolina Lineberger Comprehensive Cancer Center, to lead the National Cancer Institute. The oncologist and geneticist will succeed Doug Lowy, who has been acting director of NCI since early 2015. Lowy is expected to remain at the institute as...Read the Full Article
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients with extensive stage small-cell lung cancer (SCLC) will be...Read the Full Article
RESEARCH TRIANGLE PARK, N.C., May 16, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has...Read the Full Article
200 Patients Enrolled Exceeds Target, Top Line Results are Expected in Mid-2018 ATLANTA, GA--(May 17, 2017) - Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare pulmonary diseases, announced today the full enrollment of its phase 2b clinical trial testing its flagship anti- inflammatory drug...Read the Full Article
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that the first patient has been dosed in AURORA, the Company’s Phase 3 confirmatory clinical trial evaluating voclosporin for the treatment of lupus nephritis (LN), an autoimmune...Read the Full Article
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of George M. Milne, Jr., Ph.D. to its board of directors. Prior to his retirement, Dr. Milne served as Executive Vice President of...Read the Full Article
RESEARCH TRIANGLE PARK, N.C. -- G1 Therapeutics, Inc. (“G1” or the “Company”), a clinical-stage oncology company, today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”). The offering consists of...Read the Full Article
MONTREAL, May 1, 2017 /CNW/ - enGene Inc. announced today that Theresa Podrebarac, MD, has joined the company as Chief Medical Officer. In her new position, Dr. Podrebarac will be responsible for designing and executing clinical development plan for enGene's pipeline of products, as well as effectively positioning these novel therapeutics in...Read the Full Article
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”) today announced the pricing of its initial public offering of 4,500,000 common shares at a price to the public of U.S.$13.00 per share. In addition, Zymeworks has granted the underwriters a 30-day over-allotment option to purchase up to an additional 675,000 common shares at the initial...Read the Full Article
• enGene's proprietary PD-L1 gene therapy is being developed as potential novel therapy for acute GvHD • Late-breaking abstract on preclinical data from PD-L1 program will be presented at Digestive Disease Week (DDW) 2017 in Chicago MONTREAL, April 28, 2017 /CNW/ - enGene Inc., a biotechnology company developing a robust platform to...Read the Full Article
WOODRIDGE, IL – March 22, 2017- Endotronix, Inc., a digital health medtech company providing innovative solutions for patients who suffer from advanced heart failure, today announced the expansion of their management team. Recent hires include experienced medtech executives Katrin Leadley, MD, Chief Medical Officer (CMO), Richard Powers, Chief Information Officer (CIO), and...Read the Full Article
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing of its previously announced underwritten public offering of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters’ option...Read the Full Article
Monday, March 13, 2017 Louis Laflamme, President & Chief Executive Officer, Opsens Inc. (OPS), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to open the market. Opsens focuses mainly on the measure of Fractional Flow Reserve (FFR) in interventional cardiology. Opsens offers an optical-based pressure guidewire (OptoWire) that aims...Read the Full Article
TORONTO, March 9, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has received Health Canada approval and the corresponding medical device license (#98667) to sell its ExactVu™ high resolution micro-ultrasound system. "We are very pleased...Read the Full Article
Learn More-External LinkRead the Full Article
QUEBEC CITY, Feb. 28, 2017 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has received final approval for the listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX"). The Common Shares will commence trading on...Read the Full Article
SAN CARLOS, Calif., Jan. 25, 2017 /PRNewswire/ -- BAROnova, Inc., announced completion of its randomized cohort enrollment in the ENDObesity II Study, a multicenter randomized pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® (TPS®), which treats obesity. Richard Rothstein, MD, the lead investigator of the study...Read the Full Article
Learn More-External LinkRead the Full Article
Atlanta, GA. – Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases, announced today the appointment of Dr. Abel De La Rosa to the company board of directors. He currently serves as Chief Scientific Officer for the Drug Innovations Venture at Emory (DRIVE)...Read the Full Article
January 05, 2017 05:00 AM Eastern Standard Time VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced the successful achievement of a research milestone in a second immune-modulating bispecific antibody in...Read the Full Article
TORONTO, Jan. 5, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has secured CDN $21.5 million in a Series C investment to commercialize its ExactVu™ micro-ultrasound system. The financing, which closed late in 2016, was...Read the Full Article